Welcome to our dedicated page for Tandem Diabetes news (Ticker: TNDM), a resource for investors and traders seeking the latest updates and insights on Tandem Diabetes stock.
Tandem Diabetes Care (TNDM) delivers innovative insulin management solutions through advanced pump technology and connected diabetes care platforms. This news hub provides investors and healthcare professionals with timely updates on corporate developments, product milestones, and regulatory progress.
Access official press releases covering quarterly financial results, new product clearances, and strategic partnerships alongside analysis of market trends impacting diabetes care technology. Our curated collection ensures you stay informed about pump software updates, clinical trial outcomes, and international expansion efforts.
Key updates include FDA submissions, insulin delivery system enhancements, and operational developments across global markets. Bookmark this page for direct access to Tandem Diabetes' latest announcements, including pump compatibility improvements and user experience initiatives that shape modern diabetes management.
Tandem Diabetes Care (NASDAQ: TNDM) is set to present early user insights on its new Tandem Mobi System at the American Diabetes Association’s 84th Scientific Sessions from June 21-24 in Orlando, Florida.
The Product Theater session, scheduled for June 22, will feature presentations by key medical experts on the benefits of Tandem Mobi, the world's smallest durable Automated Insulin Delivery (AID) system, and its Control-IQ algorithm. The presenters will discuss the system's unique wearability and potential to improve patient outcomes.
Additional poster presentations will cover various studies on the t:slim X2 insulin pump with Control-IQ Technology and the Tandem t:connect mobile application.
Tandem Diabetes Care will also exhibit at Booth #1621, showcasing the Tandem Mobi and t:slim X2 systems, both compatible with multiple Continuous Glucose Monitors (CGMs).
Tandem Diabetes Care announced the compatibility of its Tandem Mobi insulin pump with both Dexcom G7 and G6 CGM systems.
This integration enhances user flexibility, allowing choice in diabetes management. Tandem Mobi, the smallest automated insulin delivery system, launched in the U.S. earlier in 2023, offers greater discretion and comfort.
Users will receive free software updates for this feature via email. New pumps will ship with the updated software pre-loaded.
This move strengthens Tandem's partnership with Dexcom and builds on their decade-long collaboration in providing innovative diabetes solutions.
Tandem Diabetes Care (NASDAQ: TNDM) will present a company update at the Jefferies Global Healthcare Conference on June 6, 2024, at 8:00 am Eastern Time (5:00 am Pacific Time).
The update will be webcast live, with an archive available for 30 days on the company’s Investor Center website.
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) reported a 13% increase in worldwide GAAP sales to $191.7 million and a 12% increase in non-GAAP sales to $192.8 million for the first quarter of 2024. The company launched Tandem Mobi with Dexcom G6 CGM sensor integration and t:slim X2 with Abbott Freestyle Libre 2 Plus CGM sensor integration in the US, among other initiatives. The increase in pump shipments and financial results showcased positive growth. However, the company reported a net loss for the quarter.
Tandem Diabetes Care, Inc. (TNDM) will present at investor conferences on May 15 and May 29, 2024, providing company updates. The presentations will be webcast live and archived for 30 days.
FAQ
What is the current stock price of Tandem Diabetes (TNDM)?
What is the market cap of Tandem Diabetes (TNDM)?
